Watchlist · 65/100Aug 13, 12:49 PM EDT
Abeona Therapeutics Reports Q2 2026 Progress: ZEVASKYN Expansion and Margin Targets
ABEO
Abeona Therapeutics (ABEO) provided Q2 2026 updates, highlighting the activation of seven qualified treatment centers (QTCs) for ZEVASKYN, including Cincinnati Children's, and reaffirming confidence in the product's commercial potential. Management also outlin…
- ▹ZEVASKYN is commercialized with growing patient treatments and 7 activated QTCs, indicating real demand and reimbursement progress.
- ▹Single-asset focus and early commercial stage cap upside, but no major regulatory negatives and steady-state gross margin target support watchlist status.
Neutral · 62/100Aug 13, 3:18 PM EDT
Pelthos Targets Q1 2027 XEPI Launch as ZELSUVMI Scripts Jump 48%
PTHS
Pelthos Therapeutics (PTHS) reported strong Q2 2026 results, with ZELSUVMI prescriptions rising 48%, and outlined plans to launch XEPI in Q1 2027. The company's revenue growth and pipeline progress signal potential upside for investors, making this a key devel…
- ▹ZELSUVMI prescriptions rising 48% indicates commercial traction, but XEPI launch not until Q1 2027, limiting near-term upside.
- ▹Single-asset focus and lack of platform differentiation cap technology score; manufacturing unknown defaults to 7.
Neutral · 57/100Aug 13, 12:59 PM EDT
Karyopharm Eyes Q1 2027 Myelofibrosis Launch, Projects Up to $1B U.S. Peak Sales
KPTI
Karyopharm Therapeutics (KPTI) announced during its Q2 2026 earnings call that it is targeting a potential approval and launch of selinexor for myelofibrosis as early as Q1 2027, with U.S. peak revenue estimated at up to ~$1 billion. The company is advancing t…
- ▹Potential approval in Q1 2027 for myelofibrosis with significant peak revenue opportunity, but regulatory path still uncertain.
- ▹Single-asset company with limited pipeline diversification and no recent BD/M&A, capping technology and narrative scores.
Neutral · 51/100Aug 13, 2:48 PM EDT
ADC Therapeutics Extends Cash Runway to 2028, Weighs Next Steps for LOTIS-5
ADCT
ADC Therapeutics (ADCT) reported Q2 2026 results, with ZYNLONTA commercial performance consistent with recent quarters. Management highlighted a cash runway extending into 2028 and is evaluating the regulatory path for LOTIS-5, a key pipeline asset. This provi…
- ▹ZYNLONTA commercial performance stable, but no growth; regulatory path for LOTIS-5 uncertain.
- ▹Cash runway into 2028 reduces near-term dilution risk, but single-asset focus and lack of major catalysts cap upside.
Neutral · 50/100Aug 13, 2:59 PM EDT
INOVIO Surges 18% on Strong Q2 Results and FDA Progress for Lead Candidate
INO
INOVIO's shares jumped 18% after reporting a Q2 loss of $0.07 per share, significantly beating analyst expectations by $0.15. The company also highlighted progress for its lead candidate INO-3107 in FDA review, with $36.7 million in cash to fund operations.
- ▹INO-3107 advancing through FDA review, but no clear accelerated path or regulatory catalyst.
- ▹Single-asset focus, limited cash runway, and dilution risk cap upside.
Neutral · 50/100Aug 13, 2:59 PM EDT
Cellectar Sets Sights on Mid-2027 NDA for Iopofosine in WM, Secures Up to $140M in Financing
CLRB
Cellectar Biosciences (CLRB) plans to submit an NDA for iopofosine I 131 in relapsed/refractory Waldenström's macroglobulinemia by mid-2027, targeting accelerated approval. The company has secured up to $140 million in financing to support the program, which f…
- ▹Accelerated approval path targeted for mid-2027 with financing secured, but single-asset and no FDA clarity yet.
- ▹Platform potential with radiopharmaceuticals, but limited commercial traction and manufacturing details.
High Risk · 47/100Aug 13, 1:48 PM EDT
MiNK Therapeutics Accelerates ARDS Trial Enrollment, Targeting 4-8 Patients Per Site Monthly Starting in September
INKT
MiNK Therapeutics (INKT) announced that enrollment for its randomized Phase 2 study of agenT-797 in acute lung injury and ARDS will begin in the U.S. in September, with a target of 4-8 patients per site per month. This marks a key execution milestone for the c…
- ▹Early-stage single-asset company with no FDA regulatory clarity; phase 2 trial in ARDS is a high-risk indication.
- ▹Limited commercial potential until proof-of-concept; manufacturing unknown, but platform technology provides some differentiation.
High Risk · 45/100Aug 13, 6:00 PM EDT
Valneva Projects $145M-$160M in 2026 Revenue, Pfizer Eyes Lyme Data Within a Year
INRLFVALN
Valneva SE (VALN) provided 2026 revenue guidance of $145M-$160M, citing strong cash position of over EUR 120 million after reinforcing its balance sheet. Pfizer is expected to make key decisions on the Lyme disease program within 12 months, a critical catalyst…
- ▹Lyme Phase III uncertainty and balance sheet concerns weigh on regulatory and narrative scores.
- ▹Pfizer partnership provides some commercial and manufacturing support, but single-asset risk and cash runway issues cap upside.
High Risk · 45/100Aug 13, 4:28 PM EDT
After-Hours Watch: AMAT, DLO, ZNTL in Focus as S&P 500 Hits New High
AMATDLOSP500COMP:IND
The S&P 500 reached a fresh all-time high on Thursday after July producer prices were unchanged month-over-month, easing inflation concerns. Investors are now watching after-hours movers including Applied Materials (AMAT), DLocal (DLO), and Zentalis (ZNTL) for…
- ▹Generic market update with no specific company news; low signal for biotech investment.
- ▹No regulatory, technology, or commercial catalysts identified; narrative penalized for lack of specificity.
High Risk · 42/100Aug 13, 4:19 PM EDT
Zentalis Announces New Stock Offering to Boost Pipeline Funding
ZNTL
Zentalis Pharmaceuticals (ZNTL) has launched an underwritten public offering of common stock and pre-funded warrants, with an option for underwriters to purchase an additional 15% of shares. Proceeds will support clinical and preclinical programs, regulatory a…
- ▹Dilution risk from public offering
- ▹Single-asset micro-cap with no clear near-term catalysts
High Risk · 40/100Aug 13, 1:11 PM EDT
Monopar Therapeutics Downgraded to Neutral by Cantor Fitzgerald
MNPRXBI
Cantor Fitzgerald downgraded Monopar Therapeutics (MNPR) to Neutral from Overweight, citing that the stock is now fairly valued after a nearly 90% rally in the past six months. This downgrade reflects a cautious stance on near-term upside, which could impact i…
- ▹Downgrade on valuation after 90% rally, indicating limited upside.
- ▹Clinical-stage single-asset company with no regulatory catalysts mentioned.